BMEA | Biomea Fusion, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	7.02 - 7.46
52 Week Range	3.61 - 21.57
Beta	-0.45
Implied Volatility	283.40%
IV Rank	93.09%
Day's Volume	197,721
Average Volume	759,990
Shares Outstanding	36,238,700
Market Cap	262,368,188
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-04-16

Valuation
Profitability
Growth
Health
P/E Ratio	-1.81
Forward P/E Ratio	N/A
EPS	-4.01
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	112
Country	USA
Website	BMEA

Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

BMEA's peers: ACLX, ALXO, ARCT, EWTX, HOWL, CGEM, DSGN, IKNA, EYPT, FDMT, FGEN, GOSS, KOD, NERV, OMER, RANI, TNYA, TSHA, VIRX, IRON, GPCR

*Chart delayed

Analyzing fundamentals for BMEA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see BMEA Fundamentals page.

Watching at BMEA technicals we can see that long-term trend is bearish, while middle-term trend is bullish, but short-term trend is bearish. More technicals details can be found on BMEA Technicals page.